The North America Peripheral Vascular Devices Market, valued at USD 4,200 Million in 2025, is projected to reach USD 8,250 Million by 2035, growing at a CAGR of 6.7% from 2024 to 2035. This market growth is driven by technological innovation, rising cardiovascular diseases, and increasing adoption of minimally invasive procedures.
The economic impact of tariffs on "North America Peripheral Vascular Devices Market".
Market Growth Drivers
Adoption of Minimally Invasive Procedures: The increasing shift towards minimally invasive surgeries for peripheral vascular diseases is driving market growth. Companies like Boston Scientific and Medtronic have introduced advanced peripheral stents and angioplasty balloons that reduce recovery time and complications. These minimally invasive solutions offer improved efficacy and patient comfort, thereby boosting demand.
Rising Prevalence of Cardiovascular Diseases: The prevalence of conditions such as peripheral arterial disease (PAD) and diabetes-related vascular complications is rising in North America. Abbott Laboratories, for example, has leveraged this trend by launching new drug-coated balloons and atherectomy devices that address complex arterial blockages, helping to fuel market expansion.
Market Trends
Integration of Artificial Intelligence and Digital Health: Companies like Philips and Siemens Healthineers are integrating AI-driven imaging, navigation systems, and digital platforms to enhance procedural planning and outcomes in peripheral vascular interventions. This digital transformation is enabling more personalized care and improved diagnostic accuracy.
Expansion of Endovascular Procedures: A growing trend towards endovascular over open surgeries is noted as hospitals and outpatient centers increasingly rely on devices such as stent grafts and thrombectomy catheters. Cook Medical and Bard (BD) are at the forefront, developing innovative endovascular devices tailored for complex anatomies, thus widening their application scope.
Market Opportunities
Expanding Target Patient Population: With an aging population and lifestyle risk factors on the rise, the potential patient base for peripheral vascular devices is growing. Companies like Terumo are investing in R&D to tap into unexplored patient cohorts and emerging indications.
Telemedicine and Remote Monitoring: The increasing acceptance of telemedicine opens opportunities for monitoring vascular device performance post-procedure, with companies such as iRhythm and Medtronic integrating remote monitoring solutions into their vascular device platforms.
North America Peripheral Vascular Devices Market Revenue (USD Million), 2020-2035
The chart illustrates a steady rise in market revenue from USD 2,950 Million in 2020 to USD 8,250 Million by 2035. The market demonstrates strong growth, particularly after 2025, driven by technological advancements, growing disease burden, and rising adoption of novel devices. Revenue growth accelerates notably post-2030, reflecting increased market penetration and expanded indications for peripheral vascular devices.
North America Peripheral Vascular Devices Market Share by Region (%) - 2025
The pie chart for 2025 shows the United States dominating with a 72% market share, thanks to a sophisticated healthcare infrastructure, higher adoption rates, and the presence of leading manufacturers. Canada follows with 16%, supported by expanding reimbursement policies. Mexico captures 7% as public health investment grows. The remaining 5% is split among Greenland, Bermuda, and other parts of the region, reflecting emerging opportunities but smaller current adoption.
Recent Market Developments
In May 2024, Medtronic announced FDA clearance for its next-generation drug-eluting stent system, catering to complex peripheral arterial disease cases. This approval is expected to strengthen Medtronic's market positioning and broaden its product portfolio.
In April 2024, Boston Scientific completed the acquisition of a leading US-based vascular access technologies company. This move is anticipated to enhance Boston Scientific's minimally invasive solutions portfolio and accelerate its market expansion across North America.
In January 2024, Abbott received Health Canada approval for its latest endovascular catheter, designed for the treatment of challenging below-the-knee lesions. The device has already shown excellent clinical outcomes in trials, reflecting Abbott’s innovation focus.
Press Releases